Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease
| Autor: | George V. Papatheodoridis, Chrysoula Pipili, Evangelos Cholongitas |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Guanine Organophosphonates Renal function Pharmacology Antiviral Agents Gastroenterology Hepatitis B Chronic Internal medicine Telbivudine Adefovir Humans Medicine Pharmacology (medical) Renal Insufficiency Chronic Tenofovir Kidney Hepatology business.industry Adenine virus diseases Lamivudine Nucleosides Entecavir Hepatitis B medicine.disease medicine.anatomical_structure business Thymidine medicine.drug Kidney disease |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 39:35-46 |
| ISSN: | 0269-2813 |
| Popis: | Summary Background The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (lamivudine, telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues (NAs), but it may be complex and the information is scarce. Entecavir and tenofovir represent the currently recommended first-line NAs for NA-naive CHB patients, while tenofovir is the NA of choice for CHB patients with resistance to nucleosides. Aim To review the efficacy and safety of NAs in adult CHB patients with CKD and to provide reasonable recommendations for their optimal management. Methods Literature search in PubMed/Medline and manual search of relevant articles, reviews and book chapters. Results NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text